# \[e-drug\] Generic quality (cont) **URL:** \ **Category:** e-drug\ **Created:** [February 20, 2001, 11:16pm UTC](https://talk.edrugplus.org/t/e-drug-generic-quality-cont/10420 "2001-02-20T23:16:19Z")\ **Posts on this page:** 1\ **Page:** 1
**Author:** ![Francisco\_Rossi](https://avatars.discourse-cdn.com/v4/letter/f/50afbb/32.png) [@Francisco\_Rossi](https://talk.edrugplus.org/u/Francisco_Rossi)\ **Post date:** [February 20, 2001, 11:16pm UTC](https://talk.edrugplus.org/t/e-drug-generic-quality-cont/10420/1 "2001-02-20T23:16:19Z")
E-drug: Generic quality (cont) --------------------------------------------- Dear Friends: I think is necessary to point out that quality of drugs is a problem in developing countries, both for brand and generic drugs. In South America there are a lot of examples about substandard drugs, brand and generic. Maybe special experiences, Peru in 1992, Ecuador some years later, under a special government programs, generated a quality problems idea about generics. There were problems with a great quantity of imported chinese generics, but now, in most countries, special programs do not exist more, and they turn to regulatory measures, like mandatory generic prescription, generic name in labels and pharmacy substitution. In this case, discussions about quality, usually refers to bioequivalence. But in most of the cases, are a part of a "war against generics", by brand based companies. Bioequivalence is important but only in a little number of cases. Doctors are the target of this war. If any country wants to promote competition with generics, is necessary to take care about quality guaranties system and information to doctors. But quality is not only a generic problem, because of generic name. Dr Francisco Rossi PAHO (?) "Francisco Rossi" \ [Please include signature, current affiliation and address with each message.BS] -- Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'. Mail administrative requests to `majordomo@usa.healthnet.org'. For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.